Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Up 828.4% in March

Mustang Bio, Inc. (NASDAQ:MBIO) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 389,000 shares, an increase of 828.4% from the February 29th total of 41,900 shares. Currently, 5.1% of the shares of the company are sold short. Based on an average daily volume of 144,100 shares, the days-to-cover ratio is presently 2.7 days.

Mustang Bio Price Performance

Shares of Mustang Bio stock traded up $0.09 during trading on Thursday, hitting $1.03. The stock had a trading volume of 40,116 shares, compared to its average volume of 145,216. The firm has a market cap of $10.75 million, a P/E ratio of -0.17 and a beta of 1.60. The business has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.54. Mustang Bio has a fifty-two week low of $0.90 and a fifty-two week high of $8.17.

Institutional Trading of Mustang Bio

Several institutional investors have recently modified their holdings of the company. Barclays PLC acquired a new stake in shares of Mustang Bio in the second quarter worth $26,000. Cetera Advisor Networks LLC bought a new position in shares of Mustang Bio in the 2nd quarter valued at approximately $31,000. BNP Paribas Arbitrage SA raised its stake in shares of Mustang Bio by 471.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 53,718 shares of the company’s stock valued at $31,000 after acquiring an additional 44,312 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Mustang Bio by 43.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 86,932 shares of the company’s stock valued at $51,000 after acquiring an additional 26,465 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Mustang Bio in the 4th quarter worth approximately $56,000. Institutional investors and hedge funds own 9.95% of the company’s stock.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.